ORDERING INFORMATION | REIMBURSEMENT | NEWS AND EVENTS | CONTACT US | BRACCO.COM     SEARCH
BRACCO DIAGNOSTICS INC.
Sign In
​​​​​​

PUBLICATIONS

Morgan DE, Spann JS, Lockhart ME, Winningham B, Bolus DN. Assessment of adverse reaction rates during gadoteridol-enhanced MR imaging in 28,078 patients. Radiology. 2011 Apr;259(1):109-16. Epub 2011 Jan 19.

Download abstract

Idee JM, Port M, Robic C, Medina C, Sabatou M, Corot C. Role of thermodynamic and kinetic parameters in gadolinium
chelate stability. J Magn Reson Imaging. 2009;30:1249-1258.

 Download abstract

Frenzel T, Lengsfeld P, Schirmer H, Hotter J, Weinmann H. Stability of gadolinium-based magnetic resonance imaging
contrast agents in human serum at 37°C. Invest Radiol. 2008;43:817-828.

Download abstract

Gibby WA, Gibby KA, Gibby WA. Comparison of Gd-DTPA-BMA (Omniscan) versus Gd HP-D03A (ProHance) retention
in human bone tissue by inductively coupled plasma atomic emission spectroscopy. Invest Radiol. 2004;39:138-142.

Download abstract

Prince MR, Erel HE, Lent RW, et al. Gadodiamide administration causes spurious hypocalcemia.
Radiology. 2003;22:639-646.

Download abstract

Tweedle MF. Physicochemical properties of gadoteridol and other magnetic resonance contrast agents.
Invest Radiol. 1992;27(SuppI.1):S2-S6.

 Download abstract

 

 

 
​​​​​​​​​​​​
.

PROHANCE INDICATIONS AND USAGE
Central Nervous System
ProHance (Gadoteridol) Injection is indicated for use in MRI in adults and children over 2 years of age to visualize lesions with abnormal vascularity in the brain (intracranial lesions), spine and associated tissues.

Extracranial/Extraspinal Tissues
ProHance is indicated for use in MRI in adults to visualize lesions in the head and neck.

IMPORTANT SAFETY INFORMATION

WARNING: NEPHROGENIC SYSTEMIC FIBROSIS
Gadolinium-based contrast agents (GBCAs) increase the risk for NSF among patients with impaired elimination of the drugs. Avoid use of GBCAs in these patients unless the diagnostic information is essential and not available with non-contrasted MRI or other modalities. NSF may result in fatal or debilitating systemic fibrosis affecting the skin, muscle and internal organs.

  • The risk for NSF appears highest among patients with:
    • chronic, severe kidney disease (GFR <30 mL/min/1.73m2), or
    • acute kidney injury.
  • Screen patients for acute kidney injury and other conditions that may reduce renal function. For patients at risk for chronically reduced renal function (e.g. age > 60 years, hypertension or diabetes), estimate the glomerular filtration rate (GFR) through laboratory testing.
  • For patients at highest risk for NSF, do not exceed the recommended ProHance dose and allow a sufficient period of time for elimination of the drug from the body prior to re-administration [See Warnings ]

As with all paramagnetic agents, caution should be exercised in patients with deoxygenated sickle erythrocytes and renal insufficiency with or without hepatic impairment. The possibility of a reaction, including serious, life threatening, or fatal, anaphylactic or cardiovascular reactions, or other idiosyncratic reactions, should always be considered, especially in those patients with a history of a known clinical hypersensitivity or a history of asthma or other allergic disorders.

Please consult full Prescribing Information for ProHance including boxed WARNING contained within this website.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch or call 1-800-FDA-1088.

All trademarks and registered trademarks are the property of their respective owners.

MultiHance is manufactured for Bracco Diagnostics Inc. by BIPSO GmbH – 78224 Singen (Germany) and by Patheon Italia SpA, Ferentino, Italy.
ProHance is manufactured for Bracco Diagnostics Inc. by BIPSO GmbH – 78224 Singen (Germany).